LIF and systemic lupus erythematosus: So far, crosses of the lupus prone mouse line MRL/lpr with either complement factor B, factor D or MASP-1/3 knockout mice demonstrated a significant benefit in targeting the alternative pathway of complement activation to reduce the severity of the renal pathology initiated by inflammation caused by immune complexes trapped in glomerular capillaries [17,18,29].